Acute Cellular Rejection and Infection Rates in Alemtuzumab vs Traditional Induction Therapy Agents for Lung and Heart Transplantation: A Systematic Review and Meta-analysis

Pharmacology, Toxicology and Pharmaceutical Science

• Acute Graft Rejection 100%
• Alemtuzumab 100%
• Basiliximab 33%
• Cystic Fibrosis 16%
• Cytomegalovirus 16%
• Epstein-Barr Virus 16%
• Fibrosing Alveolitis 16%
• Graft Rejection 16%
• Heart Muscle Ischemia 16%
• Immunosuppressive Agent 16%
• Infection Rate 100%
• Monoclonal Antibody 16%
• Observational Study 16%
• Randomized Controlled Trial 16%
• Tacrolimus 33%
• Thymocyte Antibody 33%

Medicine and Dentistry

• Odds Ratio 66%

Immunology and Microbiology

• Epstein Barr Virus 16%